Interview with Sir Andrew Dillon, Chief Executive, National Institute for Health…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Address: National Institute for Health and Clinical Excellence
1st Floor
10 Spring Gardens
London
SW1A 2BU
Tel: +44 (0)845 003 7780
The National Institute for Health and Clinical Excellence (NICE) is an NHS organisation based in London and Manchester. NICE was set up on 1 April 1999 to ensure everyone has equal access to medical treatments and high quality care from the NHS – regardless of where they live in England and Wales.
Today NICE is recognised as being a world leader in setting standards for high quality healthcare and are the most prolific producer of clinical guidelines in the world. It also produces public health recommendations on how to help improve people’s health and prevent disease. These are aimed not just at the NHS but at local authorities and all those with a remit for improving people’s health in the public, private, community and voluntary sectors.
Topics covered by NICE’ guidance range from helping people to stop smoking and encouraging them to be more physically active through to the treatment of cancer, diabetes, musculoskeletal conditions and mental health problems. NICE also makes recommendations on the use of a range of drugs.
All its recommendations are devised by independent committees. NICE’s Citizens Council is the UK’s first advisory body made up entirely of members of the public.
NICE is an independent organisation responsible for providing national guidance on promoting good health and preventing and treating ill health.
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
After several scandals that revealed longstanding deficiencies and a continual churn of executive staff, a recent independent review of leadership in the National Health Service (NHS) has uncovered a lack…
Just one year after the UK government published its Life Science Vision, outlining the ambitions of the government and the life science sector for the next 10 years, the Association…
After a tumultuous year, AstraZeneca is creating a standalone vaccine unit and will begin to charge for its COVID-19 vaccine shot, having previously provided it at cost. PharmaBoardroom looks back…
The latest news from UK pharma, including AstraZeneca’s decision to create a dedicated business unit for its COVID-19 vaccines, GSK’s raised profits forecast, and CDMO Almac’s move to create over…
Cyril Titeux, senior VP mid-sized markets EMEA & strategic leader at Janssen, argues that the current focus of many health systems on efficiency, streamlining, and reducing spending is leaving them…
British pharmaceuticals giant, GSK, one of the UK’s largest companies by market capitalization, is once again finding itself under the spotlight as analysts and shareholders alike continue to query the…
Kathy Pritchard-Jones, Professor of Paediatric Oncology at University College London (UCL) and President of the International Society of Paediatric Oncology (SIOP) discusses the latest advancements in childhood cancer treatment, the…
Zack Pemberton-Whiteley, CEO of UK-based blood cancer charity Leukaemia Care, discusses the importance of patient and patient organizations’ involvement in the decision-making process for therapy appraisals, the use of HTA,…
Stuart Evans, partner at law firm BLM and specialist in commercial disputes and litigation examines the origins and fallout of the EU/AstraZeneca vaccine dispute and why the twin forces of…
The latest UK pharma news, including how new investment in GSK stands to reshape the country’s iconic pharma giant; CDMO Sterling’s latest acquisition; and calls for a national registry to…
The first day of March 2013 also marked a first for GW Pharmaceuticals. On that day, the British biopharmaceutical company successfully listed on NASDAQ, raising over USD 30 million. Founded…
When the European Medicines Agency (EMA) relocated from London to Amsterdam after the UK announced its decision to leave the European Union, some analysts feared that Britain could become left…
See our Cookie Privacy Policy Here
